Related Experiment Video
Updated: Nov 3, 2025
07:56
Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis
Published on: May 5, 2023
547
Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies.
Hai Deng1, Ting-Xuan Tang2, Deng Chen1
1Division of Trauma & Surgical Critical Care, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Pathogens (Basel, Switzerland)
|June 2, 2021
Summary
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection causes endothelial dysfunction, leading to blood clots and inflammation in COVID-19 patients. This review explores the link between endothelial dysfunction and SARS-CoV-2, along with treatment options.
Area of Science:
- Cardiovascular Medicine
- Infectious Diseases
- Pathology
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is increasingly recognized as a systemic condition promoting a procoagulant state.
- SARS-CoV-2 infection has been shown to directly affect endothelial cells, leading to widespread inflammation and endothelial dysfunction in severe cases.
- Endothelial cells are crucial for regulating vascular homeostasis, including blood fluidity, immune cell trafficking, and platelet aggregation.
Purpose of the Study:
- To summarize the current understanding of the association between endothelial dysfunction and SARS-CoV-2 infection.
- To review the mechanisms by which SARS-CoV-2 impacts endothelial cells and contributes to vascular complications.
- To discuss potential therapeutic strategies targeting endothelial dysfunction in COVID-19.
Main Methods:
- Review of existing scientific literature and preliminary studies on COVID-19, SARS-CoV-2, and endothelial function.
- Analysis of evidence linking viral infection to endothelial cell damage and inflammation.
- Synthesis of information on the role of endothelial dysfunction in COVID-19 pathogenesis and clinical manifestations.
Main Results:
- SARS-CoV-2 infection can directly infect endothelial cells, triggering inflammation and dysfunction.
- Endothelial dysfunction contributes to vascular complications, including thrombosis and immune dysregulation, observed in COVID-19.
- Evidence suggests a strong correlation between the severity of COVID-19 and the extent of endothelial damage.
Conclusions:
- Endothelial dysfunction is a key feature of COVID-19, contributing to its systemic and prothrombotic nature.
- Targeting endothelial dysfunction presents a promising therapeutic avenue for managing COVID-19 and its vascular sequelae.
- Further research is warranted to fully elucidate the complex interplay between SARS-CoV-2 and the endothelium and to develop effective treatments.
More Related Videos
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
565
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
565
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
636
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
636
01:30Heart Failure V: Medical Management
61
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
61
01:26Coronary Artery Disease II: Pathophysiology
132
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
132
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
266
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
266
01:26Atherosclerosis III: Management
87
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
87